Dashboard
1
Poor Management Efficiency with a low ROCE of 5.62%
- The company has been able to generate a Return on Capital Employed (avg) of 5.62% signifying low profitability per unit of total capital (equity and debt)
2
Negative results in Sep 25
3
With ROE of 5.12%, it has a attractive valuation with a 3.33 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,885 Million (Mid Cap)
65.00
NA
0.00%
-0.24
5.20%
2.33
Revenue and Profits:
Net Sales:
528 Million
(Quarterly Results - Dec 2025)
Net Profit:
-6 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
24.43%
0%
24.43%
6 Months
12.88%
0%
12.88%
1 Year
20.13%
0%
20.13%
2 Years
53.55%
0%
53.55%
3 Years
14.74%
0%
14.74%
4 Years
18.21%
0%
18.21%
5 Years
-33.35%
0%
-33.35%
INKON Life Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
20.72%
EBIT Growth (5y)
17.16%
EBIT to Interest (avg)
-6.62
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.78
Tax Ratio
22.16%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.62%
ROE (avg)
3.79%
Valuation key factors
Factor
Value
P/E Ratio
65
Industry P/E
Price to Book Value
3.33
EV to EBIT
58.72
EV to EBITDA
32.28
EV to Capital Employed
4.18
EV to Sales
4.86
PEG Ratio
1.30
Dividend Yield
NA
ROCE (Latest)
7.12%
ROE (Latest)
5.12%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
527.80
514.80
2.53%
Operating Profit (PBDIT) excl Other Income
101.10
76.00
33.03%
Interest
7.50
6.30
19.05%
Exceptional Items
-46.00
0.00
Consolidate Net Profit
-6.50
32.50
-120.00%
Operating Profit Margin (Excl OI)
129.10%
83.60%
4.55%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 2.53% vs 18.64% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -120.00% vs 0.93% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,882.80
1,556.90
20.93%
Operating Profit (PBDIT) excl Other Income
320.60
216.20
48.29%
Interest
21.00
12.90
62.79%
Exceptional Items
-46.10
-6.20
-643.55%
Consolidate Net Profit
87.40
116.00
-24.66%
Operating Profit Margin (Excl OI)
106.10%
74.60%
3.15%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 20.93% vs 6.04% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -24.66% vs 16.94% in Dec 2024
About INKON Life Technology Co., Ltd. 
INKON Life Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






